PulmoSIM Therapeutics is the pharmaceutical brand of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need for combination therapies.

We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform developed by VeriSIM Life, to accelerate our drug development by bridging the translational gap between preclinical and clinical phases.